User Login | Create Account | Contact Us
March 16 – 18, 2019, Honolulu, Hawaii
Please note that slides are for review only and not to be repurposed or published.
Data + Perspectives: Clinical Investigators Explore Emerging Research and Actual Patients with Uterine Sarcomas
Introduction:Dr Love
MODULE 1: Clinical Decision-Making for Patients with Localized Uterine Leiomyosarcoma (uLMS)
Presentation — Dr Fader Cases — Dr Leitao
MODULE 2: Sequence and Selection of Currently Available Therapeutic Options for Metastatic uLMS; Future Directions
Presentation — Dr Van Tine Cases— Dr Secord
Live Poll ResultsDownload
Addressing Current Questions and Emerging Considerations with the Use of PARP Inhibitors in the Management of Ovarian Cancer
MODULE 1:Genomic Testing and Management of Primary Ovarian Cancer — Dr Moore
MODULE 2:Role of PARP Inhibition in the Management of Relapsed Ovarian Cancer — Prof Ledermann
MODULE 3:Prevention, Recognition and Management of PARP Inhibitor-Associated Side Effects — Dr Coleman
MODULE 4:Investigational Applications of Approved PARP Inhibitors; Other PARP Inhibitors in Clinical Development — Dr Lheureux
Novel Agents and Emerging Strategies in the Management of Gynecologic Cancers
MODULE 1:Biologic Rationale for and Current Research Database with Immune Checkpoint Inhibition in Gynecologic Cancers — Dr Powell
MODULE 2:Targeting Folate Receptor Alpha (FRα) in Patients with Gynecologic Cancers — Dr Birrer
MODULE 3:Other Novel Agents and Strategies Under Investigation for CC, EC and OC — Dr O’Malley
MODULE 4:Ongoing Trials Examining the Role of Anti-PD-1/PD-L1 Antibodies in Combination with Chemotherapy, Targeted Agents or Other Immunotherapeutics — Dr Westin